Peptide-Based Inhibitors for Treating Pathogenic Bacterial Infection and Granulomatous Disease

Targeting Persistent Mtb Bacilli in Lung Using Inhibitors of STAT3-IL10 Pathway

At a Glance

Researchers at Colorado State University in collaboration with the Department of Health and Human Services have developed and patented a novel treatment of patients infected with pathogenic bacterial infection or granulomatous disease using peptide-based inhibitors reducing persistent infection by more than 90%.


Current chemotherapy for tuberculosis (TB) fails to eliminate rapidly the Mycobacterium tuberculosis bacilli and to control TB globally. Treatment for drug susceptible TB today requires 6-9 months of multidrug therapy. As for TB patients with multi-drug resistant (MDR) – TB infections, treatment is endured for two years and is unsuccessful in more than 50% of the cases. To improve TB control globally, shorter, effective, and well-tolerated treatments for latent TB infection is desired as this is the only way to reduce the development of resistance against the new chemical entities.


The treatment encompasses a novel utility for IL-10 and STAT3 peptide inhibitors.  Data from animal models demonstrated that both STAT3 N-domain and IL-10R peptide inhibitors significantly reduced the persistent infecting Mycobacterium tuberculosis (Mtb) bacilli load in the lungs and modulated the lung host immune response to enhance its own bactericidal capacity infected with Mtb.


  • Commercially valuable therapeutic approach for targeting persistent infecting Mycobacterium tuberculosis (Mtb) bacilli in the lungs
  • TB therapy in combination with current standard chemotherapies
Last Updated: December 2019
Xray of ribs

Available for Licensing

IP Status

Mercedes Gonzalez-Juarrero
Nadya I. Tarasova

Reference Number
Licensing Manager

Jessy McGowan